Background: Patients with cancer have a higher incidence of cardiovascular diseases (CVDs). We aimed to evaluate the relationship between serum human epididymal protein 4 (HE4) levels and cardiovascular events in obese patients with breast cancer.
Methods: Serum HE4 levels in 316 obese patients with breast cancer were measured at baseline and then prospectively followed up for approximately 36 months. The prognostic value of serum HE4 for predicting cardiovascular events was analyzed by the Cox proportional hazard model.
Results: Serum HE4 was significantly associated with CVD history after adjustment for confounding factors (OR= 1.50; 95% CI 1.23– 3.43; P= 0.038) using multivariable logistic regression analysis. The multivariable Cox proportional hazard analysis suggested that serum HE4 had an independent prognostic value for predicting cardiovascular events in patients with breast cancer (HR=2.21, 95% CI 1.60– 5.13, P< 0.001). Additionally, sensitivity analysis showed that the independent association still existed. Stratified analysis showed that this relationship was not affected by chemoradiotherapy.
Conclusion: Serum HE4 is significantly related to cardiovascular events and poses good prognostic value for predicting cardiovascular events in obese patients with breast cancer. Serum HE4 may be a valuable indicator for the early detection of cardiovascular complications in obese patients with breast cancer.



中文翻译：

---

肥胖乳腺癌患者血清人附睾蛋白 4 水平与心血管事件的相关性

背景：癌症患者心血管疾病（CVDs）的发病率较高。我们旨在评估肥胖乳腺癌患者血清人附睾蛋白 4 (HE4) 水平与心血管事件之间的关系。
方法：在基线测量 316 名肥胖乳腺癌患者的血清 HE4 水平，然后前瞻性随访约 36 个月。采用 Cox 比例风险模型分析血清 HE4 预测心血管事件的预后价值。
结果：调整混杂因素后，血清 HE4 与 CVD 病史显着相关（OR= 1.50；95% CI 1.23–3.43；P=0.038) 使用多变量逻辑回归分析。多变量 Cox 比例风险分析表明，血清 HE4 对预测乳腺癌患者的心血管事件具有独立的预后价值（HR=2.21，95% CI 1.60-5.13，P < 0.001）。此外，敏感性分析表明，独立关联仍然存在。分层分析表明，这种关系不受放化疗的影响。
结论：血清 HE4 与心血管事件显着相关，对预测肥胖乳腺癌患者的心血管事件具有良好的预后价值。血清 HE4 可能是早期发现肥胖乳腺癌患者心血管并发症的有价值指标。